Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the last decade, the inhibition of protein-protein interactions (PPIs) has emerged from both academic and private research as a new way to modulate the activity of proteins. Inhibitors of these original interactions are certainly the next generation of highly innovative drugs that will reach the market in the next decade. However, in silico design of such compounds still remains challenging. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe this particular PPI chemical space through the presentation of 2P2I(DB), a hand-curated database dedicated to the structure of PPIs with known inhibitors. We have analyzed protein/protein and protein/inhibitor interfaces in terms of geometrical parameters, atom and residue properties, buried accessible surface area and other biophysical parameters. The interfaces found in 2P2I(DB) were then compared to those of representative datasets of heterodimeric complexes. We propose a new classification of PPIs with known inhibitors into two classes depending on the number of segments present at the interface and corresponding to either a single secondary structure element or to a more globular interacting domain. 2P2I(DB) complexes share global shape properties with standard transient heterodimer complexes, but their accessible surface areas are significantly smaller. No major conformational changes are seen between the different states of the proteins. The interfaces are more hydrophobic than general PPI's interfaces, with less charged residues and more non-polar atoms. Finally, fifty percent of the complexes in the 2P2I(DB) dataset possess more hydrogen bonds than typical protein-protein complexes. Potential areas of study for the future are proposed, which include a new classification system consisting of specific families and the identification of PPI targets with high druggability potential based on key descriptors of the interaction. CONCLUSIONS: 2P2I database stores structural information about PPIs with known inhibitors and provides a useful tool for biologists to assess the potential druggability of their interfaces. The database can be accessed at http://2p2idb.cnrs-mrs.fr.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Flow chart indicating how the 2P2IDB dataset was build from data mining. Two separate approaches were used to retrieve protein/protein complexes with known inhibitors for which structural information was available. The protein databank was search through the Dockground server [23] which led to 202 complexes that were filtered using an advanced query and manual inspection of the interface to give 9 protein/protein complexes and 25 protein/inhibitor complexes. Exhaustive search of the literature led to the discovery of 8 protein complexes corresponding to 31 protein/ligand complexes.](https://figures.cochat.ai/paper-figures/c7f8527f33f940a6a4ee7d73e37cfa85/atomic-analysis-of-protein-protein-interfaces-with-known-inhibitors-the-2p2i-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, many PPI modulators have been developed and some of these have even successfully entered the clinic [30–33].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“To date, numerous modulators have been developed to target PPIs, and many of them have successfully entered the clinic.312–316”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [312]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proceedings of the National Academy of Sciences of the United States of America
Dowling, J. E., & Wald, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06752.x · Cited by 17,893
Algorithm AS 136: A K-Means Clustering Algorithm
Hartigan, J. A., & Wong, M. A. (1979) · Applied Statistics · doi:10.2307/2346830 · Cited by 14,523 · cited 1×
“Clustering of the PPIs into three groups was performed using the K-mean method”
MethodHow many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505 · cited 1×
“The number of currently available drug targets is very limited [18].”
BackgroundPrinciples of protein-protein interactions
Jones, S., & Thornton, J. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.13 · Cited by 2,684
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 1×
“I 2 MDM2/p53 1ycr 1ycq 3 PubMed 600 [28]”
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960 · cited 2×
“preclinical stage of investigation [8,17].”
BackgroundADE-4: a multivariate analysis and graphical display software
Thioulouse, J., Chessel, D., Dole´dec, S., & Olivier, J.-M. (1997) · Statistics and Computing · doi:10.1023/a:1018513530268 · Cited by 1,620 · cited 1×
“org) and the ade4 package [25].”
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467
Journal of the Royal Statistical Society: Series C (Applied Statistics)
(2023) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1111/(issn)1467-9876 · Cited by 1,178
Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites
Laurie, A. T. R., & Jackson, R. M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti315 · Cited by 1,047 · cited 2×
“The parameters should be pre-calculated using online web servers (ProtorP [10], PDBSum [16] or Q-SiteFinder [15]) and entered on the 2P2IDB website.”
Method
Cited by
On the binding affinity of macromolecular interactions: daring to ask why proteins interact
Kastritis, P. L., & Bonvin, A. M. J. J. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0835 · Cited by 520
“Since protein–protein interfaces are larger than classical enzymatic binding sites, inhibitors or modulators that have been designed for these are also larger in size [317].”
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Smith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Druggable protein–protein interactions – from hot spots to hot segments
London, N., Raveh, B., & Schueler-Furman, O. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.011 · Cited by 223
Metadata
- Authors
- Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Morelli, Xavier
- Roche, Philippe
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-03-09
- Volume
- 5
- Issue
- 3
- Pages
- e9598
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2834754
- OpenAlex
- W2102791444
- Cited by
- 126
- References
- 48
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 15 · 2014: 11 · 2013: 22 · 2012: 20
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- protein-protein interaction, PPI inhibitors, protein-protein interfaces, hydrogen bonding, druggability assessment, structure-based drug design
- MeSH terms
- Biophysics, Humans, Hydrogen Bonding, Protein Conformation, Salts, Models, Statistical, Protein Structure, Secondary, Dimerization, Computational Biology, Internet, Principal Component Analysis, Protein Interaction Mapping, Databases, Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database. https://app.cochat.ai/papers/10.1371/journal.pone.0009598
- The paper
- Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P. (2010). Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database. PLoS ONE. https://doi.org/10.1371/journal.pone.0009598
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.